Company news
Obi Pharma, Inc. (TPEX:4174) news
Obi Pharma, Inc. news releases on 6ix. Latest, Jan 12, 2026: OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting…
Press releases & updates
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC
January 12, 2026
OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors
September 2, 2025
OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies
June 6, 2025
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC
April 30, 2025
OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, and Globo H (GH) science
April 22, 2025
OBI Pharma Receives ‘Most Promising ADC Clinical Candidate in Taiwan’ Award
March 12, 2025
OBI Pharma Enters Collaboration with GlyTech to Expand GlycOBI® Enabling Technologies Outreach in Japan and to Advance Glycan Production
December 23, 2024
OBI Pharma announces Phase 1/2 study initiation for OBI-992, a TROP2-targeted antibody drug-Conjugate for cancer therapy
June 13, 2024
OBI Pharma Announces Phase 1/2 Study Initiation for OBI-992, a TROP2-Targeted Antibody-Drug Conjugate (ADC) for Cancer Therapy
June 12, 2024
OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform
March 18, 2024
Biosion's Partner OBI Pharma Announces FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992
January 9, 2024
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992
January 3, 2024
OBI Pharma Announces Executive Leadership Management Change – Heidi Wang, Ph.D. Appointed as Chief Executive Officer
June 2, 2023
OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy
April 10, 2023
OBI Pharma : Announcement on behalf of AP Biosciences to file application for Phase I human clinical trial of Bispecific Antibody, AP203, to US FDA
August 12, 2022
OBI Pharma : Announcement of amendment of the Company's 2021 Annual Report
August 11, 2022
OBI Pharma : Announcement that the cumulative reduction of shareholding in major subsidiary, AP Biosciences, has reached more than 10%
August 8, 2022
OBI Pharma : Announcement on behalf of AP Biosciences that preemptive rights forfeited by directors are over 50% and made available to specific persons
August 8, 2022
OBI Pharma : The Company’s BOD resolved to forfeit the subscription of AP Biosciences’ cash capital increase and distribute the rights to its shareholders
August 8, 2022
OBI Pharma : forfeits subscription of AP Biosciences’ cash capital increase, distributes rights to its shareholders and sets target date
August 8, 2022